MedTrace Logo

Impact on Quality of Life From Multi-modality Lung Cancer

NCT04540757 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 66

Last updated 2022-02-03

No results posted yet for this study

Summary

The investigators aim to explore how lung cancer patients and their family carers are affected by different types of cancer treatment. The investigators are focusing on a particular type of lung cancer called Stage III N2. N2 means the cancer has spread just outside the lung to the lymph nodes. There are two main treatments available in the UK for this type of lung cancer:

1. surgery PLUS chemo radiotherapy or chemotherapy
2. radiotherapy PLUS chemotherapy Patients live for a similar length of time with either treatment option so it is difficult for patients and health professionals to know which treatment to choose. It is important to understand the impact of the treatment on patients in their daily lives. Patients will be allocated at random to receive one of the two treatments options. Patients and carers will complete questionnaires and take part in interviews. The results of this study will help the investigators decide if a larger study should be conducted in the future.

Conditions

  • Lung Neoplasms
  • Quality of Life

Interventions

PROCEDURE

Surgery

Participants will be randomised to receive surgery as part of multi-modality treatment

PROCEDURE

No surgery

Participants will be randomised to receive no surgery as part of multi-modality treatment

Sponsors & Collaborators

  • University of Manchester

    collaborator OTHER

  • The Christie NHS Foundation Trust

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-25
Primary Completion
2022-08-31
Completion
2023-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04540757 on ClinicalTrials.gov